Genmab A/S announced its financial results for the first quarter ended March 31, 2025, highlighting continued progress in its late-stage programs. The company noted that both EPKINLY and Tivdak expanded their reach with approvals in additional territories.
Genmab is maintaining its 2025 financial guidance, which was initially published on February 12, 2025. This indicates that the company's performance in the first quarter aligns with its previously communicated expectations.
The company also reported a change in its functional and presentation currency from DKK to USD, effective January 1, 2025. This change has been implemented with retrospective effect for presentation currency, with comparative figures restated accordingly.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.